These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32281679)

  • 1. COVID-19: Herd immunity and convalescent plasma transfer therapy.
    Syal K
    J Med Virol; 2020 Sep; 92(9):1380-1382. PubMed ID: 32281679
    [No Abstract]   [Full Text] [Related]  

  • 2. Convalescent plasma to treat COVID-19: Following the Argentinian lead.
    Tiberghien P; Toussirot E; Richard P; Morel P; Garraud O
    Transfus Apher Sci; 2021 Jun; 60(3):103161. PubMed ID: 34045121
    [No Abstract]   [Full Text] [Related]  

  • 3. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
    Pau AK; Aberg J; Baker J; Belperio PS; Coopersmith C; Crew P; Grund B; Gulick RM; Harrison C; Kim A; Lane HC; Masur H; Sheikh V; Singh K; Yazdany J; Tebas P;
    Ann Intern Med; 2021 Jan; 174(1):93-95. PubMed ID: 32976026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 5. Google Trends demonstrate public interest in COVID-19 convalescent plasma therapy.
    Adkins BD; Booth GS
    J Clin Apher; 2021 Jun; 36(3):492-493. PubMed ID: 33340373
    [No Abstract]   [Full Text] [Related]  

  • 6. Upper age limits for convalescent plasma donation and treatment of COVID-19 patients: A further marker of ageism.
    Fedecostante M; O'Neill D; Pierri F; Carrieri B; Lattanzio F; Cherubini A
    Transfusion; 2021 Sep; 61(9):2799-2800. PubMed ID: 34227110
    [No Abstract]   [Full Text] [Related]  

  • 7. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report.
    Cantore I; Valente P
    Transfus Apher Sci; 2020 Oct; 59(5):102848. PubMed ID: 32888822
    [No Abstract]   [Full Text] [Related]  

  • 8. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
    Betrains A; Godinas L; Woei-A-Jin FJSH; Rosseels W; Van Herck Y; Lorent N; Dierickx D; Compernolle V; Meyfroidt G; Vanderbeke L; Vergote V; Lagrou K; Verhamme P; Wauters J; Vermeersch P; Devos T; Maes P; Vanderschueren S
    Br J Haematol; 2021 Mar; 192(6):1100-1105. PubMed ID: 33314018
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report.
    Ragab D; Salah-Eldin H; Afify M; Soliman W; Badr MH
    J Med Virol; 2021 Apr; 93(4):1854-1856. PubMed ID: 33107628
    [No Abstract]   [Full Text] [Related]  

  • 10. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.
    Sahu KK; Jindal V; Siddiqui AD; Cerny J; Gerber JM
    J Med Virol; 2020 Nov; 92(11):2251-2253. PubMed ID: 32437024
    [No Abstract]   [Full Text] [Related]  

  • 11. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
    Prus K; Alquist CR; Cancelas JA; Oh D
    Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
    Vazquez SE; Bastard P; Kelly K; Gervais A; Norris PJ; Dumont LJ; Casanova JL; Anderson MS; DeRisi JL
    J Clin Immunol; 2021 Aug; 41(6):1169-1171. PubMed ID: 34009544
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
    N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
    [No Abstract]   [Full Text] [Related]  

  • 16. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19).
    Alghamdi AN; Abdel-Moneim AS
    Front Public Health; 2020; 8():437. PubMed ID: 32903641
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

  • 19. Convalescent plasma to treat COVID-19: clinical experience and efficacy.
    Pei S; Yuan X; Zhang Z; Yao R; Xie Y; Shen M; Li B; Chen X; Yin M
    Aging (Albany NY); 2021 Mar; 13(6):7758-7766. PubMed ID: 33735836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma for COVID-19 considerations.
    Adiwinata Pawitan J
    Transfus Apher Sci; 2021 Feb; 60(1):102927. PubMed ID: 32878733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.